Iradimed (NASDAQ:IRMD) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.33-$0.38 for the period, compared to the Thomson Reuters consensus estimate of $0.35. The company issued revenue guidance of $29.3-$30.0 million, compared to the consensus revenue estimate of $29.70 million.Iradimed also updated its Q1 guidance to $0.06-$0.07 EPS.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Iradimed from a buy rating to a hold rating in a research report on Saturday. Roth Capital assumed coverage on shares of Iradimed in a research report on Tuesday, October 31st. They issued a buy rating and a $16.00 price objective for the company. Finally, Credit Suisse Group assumed coverage on shares of Iradimed in a research report on Monday, November 27th. They issued a buy rating and a $19.00 price objective for the company. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $17.33.
Shares of Iradimed (IRMD) opened at $15.05 on Tuesday. Iradimed has a 52-week low of $7.85 and a 52-week high of $15.85. The stock has a market cap of $158.33, a PE ratio of 115.78 and a beta of 1.45.
In other news, Director Monty K. Allen sold 1,898 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.95, for a total transaction of $26,477.10. Following the completion of the transaction, the director now directly owns 9,062 shares of the company’s stock, valued at approximately $126,414.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 60.10% of the stock is owned by corporate insiders.
Iradimed Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.